SCHEMBL4056944

SCHEMBL4056944

CN1CCC(C(=O)NN)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HTT P42858 2/20 0.38
POLB P06746 1/20 0.38
PKM P14618 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NCF1 P14598 1/20 0.37
GNAI3 P08754 1/20 0.36
GNAO1 P09471 1/20 0.36
GNAI1 P63096 1/20 0.36
GSK3B P49841 2/20 0.36
DYRK1A Q13627 2/20 0.36
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28447489 0.81 GSK3B (0.39) HTTALDH1A1GSK3BDYRK1AWNT1
SCHEMBL28442548 0.81 HTT (0.62) HTTALDH1A1KMT2AGSK3BDYRK1A
SCHEMBL28456680 0.81 GSK3B (0.39) HTTALDH1A1GSK3BDYRK1AWNT1
SCHEMBL28444960 0.81 GSK3B (0.39) HTTALDH1A1GSK3BDYRK1AWNT1
SCHEMBL22078923 0.80 HDAC8 (0.54) MKNK1HDAC3HDAC1HDAC2HTT
SCHEMBL761339 0.80 ALDH1A1 (0.45) MKNK1HTTPKMSMN1; SMN2ALDH1A1
SCHEMBL3886733 0.79 HDAC3 (0.45) HDAC3HDAC1HDAC2SMN1; SMN2MEN1
SCHEMBL8326809 0.79 SMN1; SMN2 (0.48) MKNK1HDAC3HDAC1HDAC2PKM
SCHEMBL1119617 0.79 GNAI3 (0.51) HTTPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL14514072 0.78 SMN1; SMN2 (0.33) HTTPOLBSMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA THERAPEUTICS INC (US) 2025-11-13 US disclosed
EP-4531838-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS Kuda Therapeutics, Inc. (US) 2025-04-09 EP disclosed
EP-3663291-B1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF KARYOPHARM THERAPEUTICS INC (US) 2024-12-18 EP disclosed
WO-2023234970-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA Therapeutics, Inc. (US) 2023-12-07 WO disclosed
US-11318120-B2 Nuclear transport modulators and uses thereof BIOGEN MA INC. (US) 2022-05-03 US disclosed
US-20210251968-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF BIOGEN MA INC. (US) 2021-08-19 US disclosed
US-10925859-B2 Nuclear transport modulators and uses thereof BIOGEN MA INC. (US) 2021-02-23 US disclosed
US-10722497-B2 Nuclear transport modulators and uses thereof BIOGEN MA INC. (US) 2020-07-28 US disclosed
US-20200230110-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF BIOGEN MA INC. (US) 2020-07-23 US disclosed
EP-3663291-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Biogen MA Inc. (US) 2020-06-10 EP disclosed
WO-2013170068-A2 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF KARYOPHARM THERAPEUTICS, INC. (US) 2013-11-14 WO disclosed
CN-101023055-B Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC 2010-10-06 CN disclosed
WO-2009106753-A1 NOVEL DERIVATIVES OF 1H-INDOL-1-YL UREA, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2009-09-03 WO disclosed
EP-2078716-A1 New derivatives of 1H-indol-1-yl-urea, method for preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2009-07-15 EP disclosed
US-20090176794-A1 1H-INDOL-1-YL-UREA COMPOUNDS LES LABORATOIRES SERVIER (FR) 2009-07-09 US disclosed
US-7449462-B2 Triazole derivatives which inhibit vasopressin antagonistic activity PFIZER, INC. (US) 2008-11-11 US disclosed
US-20070203132-A1 Triazole derivatives which inhibit vasopressin antagonistic activity PFIZER INC 2007-08-30 US disclosed
US-20070197594-A1 Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2007-08-23 US disclosed
CN-101023055-A Cyclic amine derivative or salt thereof ASTELLAS PHARMA INC (JP) 2007-08-22 CN disclosed
EP-1795524-A1 CYCLIC AMINE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2007-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210251968-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPO1, XPO5, XPOT MKNK1 3315/4885HDAC3 195/4885HDAC1 279/4885
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS HIF1AN, HIF1A, EGLN2 MKNK1 828/4885HDAC3 742/4885HDAC1 318/4885
US-20070197594-A1 Cyclic amine derivative or salt thereof GRIN1, PARK7, GRIN3A MKNK1 176/4885HDAC3 2053/4885HDAC1 118/4885
US-10925859-B2 Nuclear transport modulators and uses thereof XPO1, XPO5, XPOT MKNK1 2934/4885HDAC3 130/4885HDAC1 194/4885
US-11318120-B2 Nuclear transport modulators and uses thereof XPO1, XPO5, XPOT MKNK1 3315/4885HDAC3 195/4885HDAC1 279/4885
US-20070203132-A1 Triazole derivatives which inhibit vasopressin antagonistic activity AVPR2, PRLHR, AVPR1A MKNK1 1806/4885HDAC3 485/4885HDAC1 976/4885
US-20200230110-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPO1, XPO5, XPOT MKNK1 2934/4885HDAC3 130/4885HDAC1 194/4885
US-10722497-B2 Nuclear transport modulators and uses thereof XPO1, XPO5, KPNB1 MKNK1 3049/4885HDAC3 129/4885HDAC1 164/4885
US-20090176794-A1 1H-INDOL-1-YL-UREA COMPOUNDS TPH1, HTR1D, IDO1 MKNK1 2593/4885HDAC3 1725/4885HDAC1 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.